GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: 3003-005 | Darzalex® | HuMax-CD38 | JNJ-54767414
daratumumab is an approved drug (FDA (2015), EMA (2017))
Compound class:
Antibody
Comment: Daratumumab is a monoclonal antibody directed against CD38.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Immunopharmacology Comments |
| Daratumumab acts to selectively deplete cells with high CD38 expression such as plasmablasts, plasma cells, early B-cell stages, and activated mature B cells. It is approved to treat multiple myeloma and light chain amyloidosis, and has been suggested for therapeutic potential in auto-antibody-mediated diseases (via depletion of auto-antibody-producing plasma cells) [3,6]. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Multiple myeloma |
Disease Ontology:
DOID:9538 OMIM: 254500 |
Approved therapeutic for MM. | |
